New B+L owners to make deep job cuts


Canada's Valeant Pharmaceuticals, new owner of Bausch + Lomb (B+L), the company will reduce its workforce by as much as 15% worldwide, move B+L's headquarters, and combine B+L's three business units into one operation.


New York-Canada's Valeant Pharmaceuticals is officially the new owner of Bausch + Lomb (B+L) as of Aug. 6. Valeant says that, as part of its $8.7 billion acquisition of B+L, the company will reduce its workforce by as much as 15% worldwide. Those cuts could total between 1,850 and 2,775 people on both the Valeant and B+L sides.

State, federal, and local officials sent a letter to Valeant management last week, expressing disappointment in the company’s plan to relocate B+L.

“The talent and work ethic here made Bausch and Lomb what it is today and gave this business a home for more than a century. The Rochester families behind this company deserve better than losing their jobs through no fault of their own,” said Sen. Kirsten Gillibrand (D-NY) in a statement.

At one time, Rochester was home to a trio of major companies-the others being Eastman Kodak Co. and Xerox Corp.-that ruled the local economy. With B+L’s departure imminently apparent, it will leave a massive hole in the regional job picture.

Valeant also will combine B+L’s three businesses units-pharmaceuticals, surgical equipment, and contact lenses-into a combined B+L Eye Health operation.

Further, although Valeant will remain based in Laval, Quebec, it will move B+L’s headquarters to New Jersey from Rochester, NY. The new owner states it will not close any U.S. manufacturing sites. B+L has plants in Rochester; Tampa, FL; St. Louis; Greenville, SC; and Waterford, Ireland. Valeant will continue to operate all of its current U.S. manufacturing locations, including those in Rochester.

Related Videos
The ins and outs of fitting multifocal contact lenses with Dr Jessica Crooker
Related Content
© 2023 MJH Life Sciences

All rights reserved.